SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 184.82-2.0%Dec 5 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (18521)4/2/1998 2:30:00 PM
From: tuck  Read Replies (1) of 32384
 
Henry,

Thanks for that info. I now remember the debate over the wording of that press release. Was the protocol for the European trial ever made public?

At least my source has the TG info right. I must say, though, that since the doses are likely lower for diabetics in which such a spike is bad, then the spike would probably not occur in those cases. Thus if the spike is my source's only "major" concern about Ligand's retinoids, we should feel pretty good about them. Only folks with cancer and diabetes, a small population, might have a problem with it.

So let's see if I've got this right. Retinoids could both elevate (per the cited press release) and lower (per the mouse data Henry posted a short while ago) TG levels. I gather it is all dose dependent and that there are two different mechanisms at work.

Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext